Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma
Child's Nervous System · 2024
DOI: 10.1007/s00381-024-06329-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Child's Nervous System, 2024. Verfasst von Ayşe Özkan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Balcali Hospital, Çukurova University, Adana, T…. Hauptthemen laut MEDLINE: Brain Stem Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized, Diffuse Intrinsic Pontine Glioma. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Pediatric diffuse intrinsic pontine glioma (DIPG) is a fatal disease associated with a median survival of < 1 year despite aggressive treatments. This retrospective study analyzed the treatment outcomes of patients aged < 18 years who were diagnosed with DIPG between 2012 and 2022 and who received different chemotherapy regimens. METHODS: After radiotherapy, patients with DIPG received nimotuzumab-vinorelbine combination or temozolomide-containing therapy. When nimotuzumab was unavailable, it was replaced by vincristine, etoposide, and carboplatin/cyclophosphamide (VECC). Temozolomide was administered as a single agent or a part of the combination chemotherapy comprising temozolomide, irinotecan, and bevacizumab. Furthermore, 1- and 3-year overall survival (OS), progression-free survival (PFS), and median OS and PFS were analyzed. RESULTS: The median age of 40 patients with DIPG was 97 ± 46.93 (23-213) months; the median follow-up time was 12 months. One and 3-year OS were 35.0% and 7.5%, respectively. Median OS was 12 months in all patients (n = 40), and it was 16, 10, and 11 months in those who received first-line nimotuzumab-vinorelbine combination (n = 13), temozolomide-based (n = 14), and VECC (n = 6) chemotherapy regimens, respectively (p = 0.360). One patient who received gefitinib survived for 16 months. Conversely, patients who never received radiotherapy and any antineoplastic medicamentous therapy (n = 6) had a median OS of 4 months. CONCLUSION: Nimotuzumab-vinorelbine combination therapy prolonged OS by 6 months compared with temozolomide-containing chemotherapy, although the difference was not statistically significant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Balcali Hospital, Çukurova University, Adana, Turkey. drayseozkan79@yahoo.com.tr.
- Department of Pediatric Hematology and Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey.
- Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Balcali Hospital, Çukurova University, Adana, Turkey.
ORCID-Profile: Ayşe Özkan, Begül Yağcı Küpeli, Serhan Küpeli, Gülay Sezgin, İbrahim Bayram
Zitieren
APA
Özkan, A., Yağcı Küpeli, B., Küpeli, S., Sezgin, G., & Bayram, İ. (2024). Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma. Child's Nervous System. https://doi.org/10.1007/s00381-024-06329-4
Vancouver
Özkan A, Yağcı Küpeli B, Küpeli S, Sezgin G, Bayram İ. Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma. Child's Nervous System. 2024. doi:10.1007/s00381-024-06329-4
BibTeX
@article{zkan2024,
author = {Özkan, Ayşe and Yağcı Küpeli, Begül and Küpeli, Serhan and Sezgin, Gülay and Bayram, İbrahim},
title = {Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma},
journal = {Child's Nervous System},
year = {2024},
doi = {10.1007/s00381-024-06329-4}
}
EUVIMED